2 most recent filings and news items mentioning FATE. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/FATE/news?limit=20"
Pull FATE filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayFate Therapeutics Inc filed amendments to its Third Amended and Restated 2022 Stock Option and Incentive Plan to facilitate equity-based compensation for officers, employees, directors and consultants. The plan modification aligns employee interests with shareholder value creatio
View filing at SEC.gov →Fate Therapeutics presented its corporate pipeline progress focusing on off-the-shelf cell therapy development with plans to commence Phase 2 studies. The advancement of novel CAR T-cell therapies represents potential clinical and commercial progress for the cell therapy company.
View filing at SEC.gov →